Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy.
cancer immunovirotherapy
drug delivery
nanohydrogel
oncolytic virus
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
08 Jan 2021
08 Jan 2021
Historique:
received:
25
11
2020
revised:
30
12
2020
accepted:
31
12
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
14
1
2021
Statut:
epublish
Résumé
Oncolytic viruses (OVs) are emerging as promising and potential anti-cancer therapeutic agents, not only able to kill cancer cells directly by selective intracellular viral replication, but also to promote an immune response against tumor. Unfortunately, the bioavailability under systemic administration of OVs is limited because of undesired inactivation caused by host immune system and neutralizing antibodies in the bloodstream. To address this issue, a novel hyaluronic acid based redox responsive nanohydrogel was developed in this study as delivery system for OVs, with the aim to protect the OVs following systemic administration. The nanohydrogel was formulated by water in oil (W/O) nanoemulsion method and cross-linked by disulfide bonds derived from the thiol groups of synthesized thiolated hyaluronic acid. One DNA OV Ad[I/PPT-E1A] and one RNA OV Rigvir
Identifiants
pubmed: 33435600
pii: nano11010144
doi: 10.3390/nano11010144
pmc: PMC7827853
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Commission
ID : 675743
Organisme : European Commission
ID : 777682
Références
Gene Ther. 2008 Jun;15(12):877-84
pubmed: 18418413
Drug Deliv. 2018 Nov;25(1):278-292
pubmed: 29334800
Nanotechnology. 2008 May 7;19(18):185707
pubmed: 21825703
J Pharmacol Toxicol Methods. 2008 Nov-Dec;58(3):222-32
pubmed: 18723098
Small. 2013 Jan 28;9(2):284-93
pubmed: 22930531
Sci Rep. 2017 Oct 26;7(1):14177
pubmed: 29074882
J Control Release. 2015 Dec 10;219:181-191
pubmed: 26453806
J Control Release. 2018 Aug 10;283:223-234
pubmed: 29864473
Clin Cancer Res. 2010 Jun 1;16(11):3035-43
pubmed: 20501623
Materials (Basel). 2020 Jan 02;13(1):
pubmed: 31906527
Adv Healthc Mater. 2013 Oct;2(10):1304-8
pubmed: 23505024
Cancer Gene Ther. 2008 Apr;15(4):203-13
pubmed: 18188185
Oncogene. 2005 Nov 21;24(52):7802-16
pubmed: 16299539
Cancer Res. 1995 Sep 1;55(17):3752-6
pubmed: 7641188
J Lipid Res. 2018 Aug;59(8):1316-1324
pubmed: 29764923
Nat Clin Pract Oncol. 2007 Feb;4(2):101-17
pubmed: 17259931
Eur J Pharmacol. 2018 Oct 15;837:117-126
pubmed: 30179611
Mol Pharm. 2019 Feb 4;16(2):779-785
pubmed: 30604617
J Gen Virol. 2009 Jan;90(Pt 1):1-20
pubmed: 19088268
Gene Ther. 2009 Dec;16(12):1395-404
pubmed: 19641532
Cancer Res. 2007 Jan 15;67(2):429-32
pubmed: 17234747
J Control Release. 2006 Jun 28;113(2):155-63
pubmed: 16764960
Hum Gene Ther Clin Dev. 2014 Mar;25(1):7-15
pubmed: 24649837
Cancer Gene Ther. 2006 Jan 1;13(1):13-20
pubmed: 16052227
Mater Sci Eng C Mater Biol Appl. 2020 Jan;106:110251
pubmed: 31753346
J Natl Cancer Inst. 1977 Jul;59(1):221-6
pubmed: 327080
J Clin Oncol. 2000 Apr;18(8):1606-13
pubmed: 10764420
Colloids Surf B Biointerfaces. 2016 Oct 1;146:396-405
pubmed: 27388968
Gene Ther. 2009 Mar;16(3):376-82
pubmed: 19092859
Biochim Biophys Acta. 1978 Jul 17;541(4):535-42
pubmed: 667134
Mol Ther. 2008 Sep;16(9):1556-64
pubmed: 18665158
J Control Release. 2019 Jan 28;294:165-175
pubmed: 30557650
N Engl J Med. 2006 Sep 14;355(11):1114-23
pubmed: 16971718
Bioorg Med Chem Lett. 2006 Aug 15;16(16):4243-5
pubmed: 16759859
J Pharm Sci. 2007 Nov;96(11):2861-78
pubmed: 17847076
Clin Cancer Res. 2007 Feb 1;13(3):977-85
pubmed: 17289893
Cancer Res. 2013 Jan 15;73(2):490-5
pubmed: 23172310
Mol Aspects Med. 2007 Feb;28(1):42-58
pubmed: 17300834
Proc Natl Acad Sci U S A. 1973 Sep;70(9):2619-23
pubmed: 16592108
Oncoimmunology. 2015 Dec 8;5(1):e1115641
pubmed: 26942095
Gene Ther. 2010 Jul;17(7):892-904
pubmed: 20237509
Mol Ther. 2010 Feb;18(2):243-50
pubmed: 19935777
Cancer Res. 2003 Jul 1;63(13):3605-11
pubmed: 12839948
Biomaterials. 2011 Aug;32(22):5223-30
pubmed: 21514660
Melanoma Res. 2015 Oct;25(5):421-6
pubmed: 26193376
Cancer. 1988 Dec 15;62(12):2507-16
pubmed: 3056604
Bioconjug Chem. 1997 Sep-Oct;8(5):686-94
pubmed: 9327132
Cancers (Basel). 2018 Sep 26;10(10):
pubmed: 30261620
BMB Rep. 2010 Dec;43(12):781-8
pubmed: 21189153
Mol Ther. 2009 Oct;17(10):1664-6
pubmed: 19789561
Gene Ther. 1999 Sep;6(9):1558-64
pubmed: 10490765
Pharm Res. 1999 Oct;16(10):1576-81
pubmed: 10554100
Bioconjug Chem. 2008 Apr;19(4):797-801
pubmed: 18363345
Curr Cancer Drug Targets. 2007 Mar;7(2):141-8
pubmed: 17346105
APMIS. 2016 Oct;124(10):896-904
pubmed: 27457663
Int J Mol Sci. 2016 Feb 06;17(2):172
pubmed: 26861303
J Control Release. 2009 Jul 1;137(1):63-8
pubmed: 19303426
J Virol. 2001 May;75(10):4792-801
pubmed: 11312351
Case Rep Gastroenterol. 2018 Aug 23;12(2):457-465
pubmed: 30283278
Nano Lett. 2019 Aug 14;19(8):5806-5817
pubmed: 31331172
Skin Res Technol. 2016 Feb;22(1):55-62
pubmed: 25877232
Cancer Gene Ther. 2002 Dec;9(12):961-6
pubmed: 12522435
J Cell Physiol. 2019 Nov;234(11):20013-20027
pubmed: 30968404
Adv Drug Deliv Rev. 2003 Feb 10;55(2):199-215
pubmed: 12564977
Virol J. 2011 Oct 14;8:473
pubmed: 21999585
J Gen Virol. 2000 Nov;81(Pt 11):2605-2609
pubmed: 11038370
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Virol. 2011 Jun;85(12):6015-23
pubmed: 21471241
Biomater Sci. 2019 Oct 1;7(10):4195-4207
pubmed: 31386700
Cancer Cell. 2003 Jul;4(1):7-11
pubmed: 12892708
Hum Gene Ther. 1999 May 20;10(8):1349-58
pubmed: 10365665
Adv Drug Deliv Rev. 2001 Dec 31;53(3):321-39
pubmed: 11744175
Biomaterials. 2014 Jul;35(21):5505-16
pubmed: 24731708
J Pharm Biomed Anal. 2003 Mar 10;31(3):545-50
pubmed: 12615242
Nanoscale Res Lett. 2018 Nov 21;13(1):370
pubmed: 30465280
Drug Chem Toxicol. 2010 Oct;33(4):357-66
pubmed: 20550436